podcasts Ratings /ratings/en/research-insights/podcasts/2020-09-21-the-sp-pharma-dose-episode-36-what-bausch-remainco-s-credit-quality-post-spinoff-could-look-like content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

Thank you for your interest in S&P Global Market Intelligence! We noticed you've identified yourself as a student. Through existing partnerships with academic institutions around the globe, it's likely you already have access to our resources. Please contact your professors, library, or administrative staff to receive your student login.

At this time we are unable to offer free trials or product demonstrations directly to students. If you discover that our solutions are not available to you, we encourage you to advocate at your university for a best-in-class learning experience that will help you long after you've completed your degree. We apologize for any inconvenience this may cause.

In This List

The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

COMMENTS

Industry Report Card: Top 20 EMEA Chemical Companies And COVID-19: The Credit Impact Relies Largely On Subsector Exposures And Responses

COMMENTS

COVID-19 Impact: Key Takeaways From Our Articles

COMMENTS

Reassessing The Pace Of Recovery For U.S. Media

COMMENTS

Economic Research: Pandemic Won’t Derail European Housing Price Rises

Listen: The S&P Pharma Dose - Episode 36: What Bausch RemainCo’s Credit Quality Post-Spinoff Could Look Like

In this episode, Ji Liu, primary analyst for Bausch Health, discusses a number of investor questions after Bausch announced its intention to spin off its eye health business unit, specifically regarding its capital structure, key business strengths, key business weaknesses, and other concerns.

Register with S&P Global Ratings

Register now to access exclusive content, events, tools, and more.

Go Back